FAQ: Why is binding CD64+ important when discussing IL23 directed therapy?

Join Sarah Enslin, PA-C, from the University of Rochester Medical Center, as she explores the latest advancements in CD64-positive cell targeting and IL-23-directed therapy. This innovative approach enhances the specificity and effectiveness of treatment for psoriasis, psoriatic arthritis, and inflammatory bowel disease (IBD) by engaging immune cells responsible for chronic inflammation.

Learn how CD64, a high-affinity receptor on monocytes, macrophages, and dendritic cells, becomes upregulated during inflammation, making it a critical target for IL-23 inhibitors. Discover the role of monoclonal antibodies like GOMAB, which neutralize IL-23 while binding to CD64-expressing cells, optimizing treatment impact, reducing inflammation, and improving patient outcomes.

For more information on the latest research in rheumatology and immunology, visit the GHAPP website or download the GHAPP ACE app.